The FDA is considering a national registry for thermal ablation treatment of breast cancer. The proposed registry would compile information on all thermal ablation devices and therapies for small carcinomas and address inconsistencies that potentially diminish the value of previously published feasibility protocols.
The FDA is considering a national registry for thermal ablation treatment of breast cancer. The proposed registry would compile information on all thermal ablation devices and therapies for small carcinomas and address inconsistencies that potentially diminish the value of previously published feasibility protocols. It would also lay out standard protocols for tumor selection, biopsy techniques, pathology studies, image guidance, and postablation assessment.
The FDA described its rationale for a registry in the May 28 Federal Register. It will accept comments on the plan until Nov. 28.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.